Madopar CR 100mg/25mg Prolonged Release Hard Capsules Malta - angļu - Medicines Authority

madopar cr 100mg/25mg prolonged release hard capsules

roche products limited 6 falcon way, shire park, welwyn garden city, al7 1tw, united kingdom - benserazide, levodopa - prolonged-release capsule - benserazide 25 mg levodopa 100 mg - anti-parkinson drugs

Madopar 50mg/12.5mg Hard Capsules Malta - angļu - Medicines Authority

madopar 50mg/12.5mg hard capsules

roche products limited 6 falcon way, shire park, welwyn garden city, al7 1tw, united kingdom - benserazide, levodopa - hard capsule - benserazide 50 mg levodopa 50 mg - anti-parkinson drugs

Madopar 100mg/25mg Hard Capsules Malta - angļu - Medicines Authority

madopar 100mg/25mg hard capsules

roche products limited 6 falcon way, shire park, welwyn garden city, al7 1tw, united kingdom - benserazide, levodopa - hard capsule - benserazide 25 mg levodopa 100 mg - anti-parkinson drugs

Madopar 200mg/50mg Hard Capsules Malta - angļu - Medicines Authority

madopar 200mg/50mg hard capsules

roche products limited 6 falcon way, shire park, welwyn garden city, al7 1tw, united kingdom - benserazide, levodopa - hard capsule - benserazide 50 mg levodopa 200 mg - anti-parkinson drugs

Madopar HBS capsule (100/25) Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

madopar hbs capsule (100/25)

roche products pty ltd - benserazide hydrochloride, quantity: 28.5 mg (equivalent: benserazide, qty 25 mg); levodopa, quantity: 100 mg - capsule, hard - excipient ingredients: mannitol; indigo carmine; iron oxide yellow; hypromellose; titanium dioxide; magnesium stearate; purified talc; gelatin; hydrogenated vegetable oil; povidone; calcium hydrogen phosphate dihydrate; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; shellac; iron oxide red; ethanol absolute; potassium hydroxide; ammonia - parkinson's disease and parkinsonian symptoms including post-encephalitic and toxic forms, but excluding drug induced parkinsonism. madopar hbs is indicated for patients presenting with all types of fluctuations in response (i.e. "peak dose dyskinesia" and "end of dose deterioration") and for better control of nocturnal symptoms.

LECTEVA levodopa/carbidopa/entacapone 200 mg/50 mg/200 mg tablet bottle Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

lecteva levodopa/carbidopa/entacapone 200 mg/50 mg/200 mg tablet bottle

teva pharma australia pty ltd - levodopa, quantity: 200 mg; carbidopa monohydrate, quantity: 54.1 mg (equivalent: carbidopa, qty 50 mg); entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose; hyprolose; povidone; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; glycerol; iron oxide yellow; polysorbate 80; iron oxide red; iron oxide black - lecteva (levodopa/carbidopa/entacapone) is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

LECTEVA levodopa/carbidopa/entacapone 175 mg/43.75 mg/200 mg tablet bottle Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

lecteva levodopa/carbidopa/entacapone 175 mg/43.75 mg/200 mg tablet bottle

teva pharma australia pty ltd - levodopa, quantity: 175 mg; carbidopa monohydrate, quantity: 47.2 mg (equivalent: carbidopa, qty 43.75 mg); entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose; hyprolose; povidone; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; glycerol; iron oxide yellow; polysorbate 80; iron oxide red; iron oxide black - lecteva (levodopa/carbidopa/entacapone) is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

LECTEVA levodopa/carbidopa/entacapone 150 mg/37.5 mg/200 mg tablet bottle Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

lecteva levodopa/carbidopa/entacapone 150 mg/37.5 mg/200 mg tablet bottle

teva pharma australia pty ltd - levodopa, quantity: 150 mg; carbidopa monohydrate, quantity: 40.5 mg (equivalent: carbidopa, qty 37.5 mg); entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose; hyprolose; povidone; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; glycerol; polysorbate 80; iron oxide red; carmoisine aluminium lake - lecteva (levodopa/carbidopa/entacapone) is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

LECTEVA levodopa/carbidopa/entacapone 125 mg/31.25 mg/200 mg tablet bottle Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

lecteva levodopa/carbidopa/entacapone 125 mg/31.25 mg/200 mg tablet bottle

teva pharma australia pty ltd - levodopa, quantity: 125 mg; carbidopa monohydrate, quantity: 33.8 mg (equivalent: carbidopa, qty 31.25 mg); entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose; hyprolose; povidone; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; glycerol; iron oxide yellow; polysorbate 80; iron oxide red - lecteva (levodopa/carbidopa/entacapone) is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

LECTEVA levodopa/carbidopa/entacapone 100 mg/25 mg/200 mg tablet bottle Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

lecteva levodopa/carbidopa/entacapone 100 mg/25 mg/200 mg tablet bottle

teva pharma australia pty ltd - levodopa, quantity: 100 mg; carbidopa monohydrate, quantity: 27 mg (equivalent: carbidopa, qty 25 mg); entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose; hyprolose; povidone; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; glycerol; polysorbate 80; allura red ac aluminium lake; carmine - lecteva (levodopa/carbidopa/entacapone) is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.